Syngene Posts 13% Sequential Revenue Growth in Q2 FY27, Signs First Manufacturing Deal for US Bayview Biologics Plant

Syngene International’s Q2 FY27 revenue rose 13% quarter-on-quarter to ₹833 crore and operating EBITDA margin improved six points to 18%, helped by CDMO traction, while the company signed its first manufacturing agreement for its Bayview biologics facility in the US.